Celon Pharma (CLN) investor relations material

Executive summary

• Total revenue for H1 2026 reached PLN 121,959 thousand, up 15% year-over-year, driven by higher sales of generic drugs and increased grant income.

• Net profit for H1 2026 was PLN 128,043 thousand, a significant turnaround from a net loss of PLN 58,131 thousand in H1 2025, mainly due to a one-time gain from the revaluation of Novohale investment.

• The generic medicines segment drove most of the revenue, while the innovative segment showed improved EBITDA but remained negative.

• EBITDA for the generic segment was PLN 29,901 thousand, reflecting stable performance.

Financial highlights

• EBITDA for H1 2026 was PLN 6,745 thousand, compared to a negative PLN 10,960 thousand in H1 2025.

• Gross profit reached PLN 152,954 thousand, reversing a gross loss of PLN 49,635 thousand year-over-year.

• Operating costs slightly decreased to PLN 137,399 thousand, with notable reductions in depreciation and raw material consumption.

• One-time gain of PLN 172,570 thousand from the revaluation of Novohale investment after loss of significant influence.

• Cash and cash equivalents increased to PLN 33,640 thousand from PLN 19,310 thousand at year-end 2025.

Outlook and guidance

• Phase 3 clinical trials for key innovative projects are planned for late 2026, with ongoing partnership discussions.

• Dossier readiness for the Reduzek® (semaglutide) generic is targeted for Q3/Q4 2026 in major markets.

• New manufacturing facility in Slovakia to be operational by Q4 2026, scaling up to 20 million pens annually.

• Management expects continued stable performance in the generic segment and ongoing development in the innovative segment, supported by external financing and grants.

• Sufficient liquidity and capital resources are in place to support operations and investments for at least the next 12 months.